Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Ciba Tegretol XR

Executive Summary

Ciba Tegretol XR: Carbamazepine extended-release tablets available for first-line treatment of partial, secondarily generalized and generalized tonic-clonic epileptic seizures. The anticonvulsant, approved March 25, will be available in 100, 200 and 400 mg tablets for twice-daily dosing. The previous version of Tegretol required three to four daily doses. Dizziness, drowsiness, unsteadiness, nausea and vomiting are most frequently observed adverse events with Tegretol formulations, the company says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel